Home › Funds › Aequim Alternative Investments LP › ALNY
Aequim Alternative Investments LP position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Aequim Alternative Investments LP reported holding 39,750,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$36.5M, representing 0.72% of its reported portfolio and ranking #31 among its reported holdings. Aequim Alternative Investments LP has disclosed ALNY holdings in 9 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aequim Alternative Investments LP's ALNY position evolved
Aequim Alternative Investments LP first disclosed a stake in ALNY in Q3 2023 at 30,000,000 shares (US$27.8M). The position peaked in Q3 2024 at 80,000,000 shares, worth US$93.7M. Across 9 filings, Aequim Alternative Investments LP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 39,750,000 shares valued at US$36.5M. Notable position changes include a 35% increase in Q4 2023 (shares fell 22% over the following quarter), a 129% increase in Q2 2024 (shares rose 13% over the following quarter), a 38% trim in Q4 2024 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 30.00M | $27.82M | New |
| Q4 2023 | 40.50M | $39.99M | Add |
| Q1 2024 | 35.00M | $33.07M | Reduce |
| Q2 2024 | 80.00M | $86.40M | Add |
| Q3 2024 | 80.00M | $93.72M | Hold |
| Q4 2024 | 50.00M | $53.27M | Reduce |
| Q1 2025 | 40.00M | $46.16M | Reduce |
| Q2 2025 | 37.50M | $48.81M | Reduce |
| Q3 2026 | 39.75M | $36.50M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
More on Aequim Alternative Investments LP
FAQ
How long has Aequim Alternative Investments LP held ALNY?
Aequim Alternative Investments LP has disclosed ALNY holdings in 9 of the last 13 reported quarters, going back to Q3 2023.
What is Aequim Alternative Investments LP's current position in ALNY?
As of Q3 2026, Aequim Alternative Investments LP holds 39.75M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $36.50M, representing 0.72% of its reported portfolio and ranking #31.
Has Aequim Alternative Investments LP been buying or selling ALNY?
In the latest 13F filing (Q3 2026), Aequim Alternative Investments LP newly opened its position in ALNY. The position peaked in Q3 2024 at 80.00M shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.